PRX003 is a monoclonal antibody under development by Prothena for the possible treatment of inflammatory diseases. It is currently being tested in patients with multiple sclerosis (MS).

Immune cells release cytokines that can trigger inflammation and are central to many inflammatory diseases. An MCAM (melanoma cell adhesion molecule) binds to a partner molecule the blood stream then then allows it to infiltrate adjacent tissues, leading to inflammation.

In healthy people, the blood-brain barrier prevents immune cells (lymphocytes) from entering the central nervous system. In people with MS, two types of lymphocytes, CD4 and CD8, find a way to cross the barrier. They then destroy the myelin sheath that protects neurons, resulting in brain lesions.

MCAM may play a crucial role in MS because it is necessary for the migration of both CD4 and CD8 lymphocytes across the blood-brain barrier. Blocking MCAM may delay the onset of MS and significantly slow its progression.

PRX003 binds to MCAM, blocks the route of inflammation, and prevents the migration of CD4 and CD8 lymphocytes into the brain tissue.

In March, Prothena completed a single ascending dose study of PRX003 in healthy participants (NCT02458677). All doses of PRX003 were reported as safe and tolerated following a single infusion up to 30 mg/kg dose. The results showed that PRX003 administration led to more than 95 percent MCAM neutralization.

Adverse effects reported were headache, balance disorder, seasonal allergies, and viral upper respiratory tract infection in 5 percent of participants.

A Phase 1b clinical study of PRX003 in people with psoriasis (NCT02630901) is ongoing.

Note: Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

NIH Awards $2.3M to Bioengineer to Advance Diagnosis, Treatment of Autoimmune Diseases

The National Institutes of Health (NIH) awarded a $2.3 million grant to a bioengineer at Indiana University’s Luddy School of Informatics, Computing and Engineering to improve diagnosis and treatment of autoimmune diseases, such as multiple sclerosis (MS). The project aims to find ways to detect disease-associated cells based on their ability to adhere, or “stick,” to others. If successful, the […]

Gilenya Remains Favorite S1P Receptor Modulator in US, But Zeposia May Catch Up, Survey Finds

Among oral sphingosine-1-phosphate (S1P) receptor modulators for multiple sclerosis (MS), Novartis’s Gilenya (fingolimod) remains physicians’ favorite in the U.S., but prescriptions of recently-launched Bristol Myers Squibb’s Zeposia (ozanimod) are beginning to rise, according to a survey conducted by Spherix Global Insights. Also, COVID-19 not only has delayed and impaired the launch of Zeposia —  approved in the U.S […]

MS News That Caught My Eye Last Week: Economic Impact Survey, Fatigue, DMTs

National MS Society Launches Survey to Assess Economic Impact of MS We know that managing MS is expensive. It can cost us money out of our pockets and also limit our ability to earn that money. A small survey about this was the subject of my “MS Wire” column last Friday. Coincidentally, the National Multiple […]

MS Prevalence at Over 2.8 Million Worldwide, Update to Atlas Reports

More than 2.8 million people worldwide are now estimated to be living with multiple sclerosis (MS), including about 1 million in the United States, an update to the Atlas of MS reports. An increase since its previous update, this number translates to someone, somewhere in the world, being newly diagnosed with the disease every five minutes, the National MS […]

Pregnancy Delays Likely MS Onset by About 3 Years, Large Study Finds

After a pregnancy or childbirth, most women who went on to develop clinically isolated syndrome (CIS) did so about three years later than those who were never pregnant, a large and multicenter study reported. Multiple pregnancies or births, however, were not seen to further affect CIS onset. More research is needed to understand the reasons pregnancy […]

Who We Are and What We Do

We’re now moving into the sixth month of quarantine, and it’s looking more and more like the world isn’t going to snap back to the way it was before all of this craziness started. I’m starting to think that’s not necessarily a bad thing, because some of the stuff going on before COVID-19 was less […]

Like Iggy Says, ‘All Aboard for Funtime’

I’ve been a moderator at MS News Today Forums for a while. One of my jobs, besides rejecting the interminable bots that try to become members, is to promote interaction. This is the hard part. The bots are amazingly easy — they are so far away from getting near the Turing Test that even the […]

MS Digs Deep Into the Wallet, Report Shows

Multiple sclerosis (MS) is expensive. Even with good insurance, those of us living in a country without universal healthcare have significant out-of-pocket costs for our treatments and medications. Some of these costs may not be covered at all. MS can put us into some serious debt, and it happens to more than just a few. […]

National MS Society Launches Survey to Assess Economic Impact of MS

The National Multiple Sclerosis Society, together with the Lewin Group, has launched a survey to assess the economic impact multiple sclerosis (MS) has on patients and their families. In the survey, which can be found here, MS patients and/or their family members are asked to answer up to 32 questions detailing their health-related expenses, including […]